Expression of Zyxin in Non-Small Cell Lung Cancer-A Preliminary Study.
non-small cell lung cancer
tumor cells
zyxin
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
13 06 2022
13 06 2022
Historique:
received:
13
05
2022
revised:
09
06
2022
accepted:
09
06
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
28
6
2022
Statut:
epublish
Résumé
The potential involvement of zyxin (ZYX) in carcinogenesis has been investigated in many cancer types. However, there are a limited number of studies on the role of ZYX in the progression of non-small cell lung cancer (NSCLC). Since lung cancer is one of the most frequently diagnosed carcinomas, the aim of our study was to determine the localization and expression levels of ZYX in NSCLC and to correlate the results with the clinicopathological data. The expression of ZYX was assessed in NSCLC cases and in cell lines representing this tumor type. Levels of ZYX were determined in the clinical material using immunohistochemistry (IHC) and Western Blot. Real-time PCR was used to assess The results showed lower levels of ZYX in NSCLC cells compared with control tissues. This trend was observed at the protein and mRNA levels. The assays on the NSCLC model also demonstrated lower levels of ZYX in cancer cells compared with control cells. The decreased expression of ZYX in NSCLC may indicate a suppressor role of this protein in NSCLC.
Sections du résumé
BACKGROUND
The potential involvement of zyxin (ZYX) in carcinogenesis has been investigated in many cancer types. However, there are a limited number of studies on the role of ZYX in the progression of non-small cell lung cancer (NSCLC). Since lung cancer is one of the most frequently diagnosed carcinomas, the aim of our study was to determine the localization and expression levels of ZYX in NSCLC and to correlate the results with the clinicopathological data.
MATERIALS AND METHODS
The expression of ZYX was assessed in NSCLC cases and in cell lines representing this tumor type. Levels of ZYX were determined in the clinical material using immunohistochemistry (IHC) and Western Blot. Real-time PCR was used to assess
RESULTS
The results showed lower levels of ZYX in NSCLC cells compared with control tissues. This trend was observed at the protein and mRNA levels. The assays on the NSCLC model also demonstrated lower levels of ZYX in cancer cells compared with control cells.
CONCLUSIONS
The decreased expression of ZYX in NSCLC may indicate a suppressor role of this protein in NSCLC.
Identifiants
pubmed: 35740950
pii: biom12060827
doi: 10.3390/biom12060827
pmc: PMC9221212
pii:
doi:
Substances chimiques
RNA, Messenger
0
ZYX protein, human
0
Zyxin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Exp Cell Res. 2006 Apr 15;312(7):1194-204
pubmed: 16510139
J Cell Physiol. 2019 Jan 29;:
pubmed: 30697742
Biochim Biophys Acta. 2015 Feb;1853(2):388-95
pubmed: 25450971
Histol Histopathol. 2005 Jan;20(1):83-9
pubmed: 15578426
Nat Commun. 2016 Mar 31;7:11123
pubmed: 27030211
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Cancer Res. 2002 Dec 1;62(23):6973-80
pubmed: 12460915
J Biol Chem. 2012 Sep 7;287(37):31393-405
pubmed: 22778267
Commun Integr Biol. 2008;1(2):192-5
pubmed: 19513257
J Proteome Res. 2015 Mar 6;14(3):1412-9
pubmed: 25597550
Exp Cell Res. 2006 Apr 15;312(7):974-82
pubmed: 16430883
Cancer Res. 2006 Aug 1;66(15):7414-9
pubmed: 16885336
Lancet Oncol. 2015 Apr;16(4):e165-72
pubmed: 25846096
Exp Cell Res. 2006 Oct 15;312(17):3425-31
pubmed: 16956606
Cancer Res. 2001 Oct 1;61(19):7101-9
pubmed: 11585741
Br J Cancer. 2007 Jan 29;96(2):296-305
pubmed: 17211471
Anal Chim Acta. 2017 Aug 22;982:84-95
pubmed: 28734369
Thorac Cancer. 2020 Jun;11(6):1522-1532
pubmed: 32301286
Anticancer Res. 2020 Nov;40(11):5981-5988
pubmed: 33109535
Nat Rev Cancer. 2014 Aug;14(8):535-46
pubmed: 25056707
Genes Cancer. 2010 May 1;1(5):506-515
pubmed: 20852740
Trends Cell Biol. 2014 Oct;24(10):575-83
pubmed: 24933506
Mol Biol Cell. 2009 Jul;20(13):3115-24
pubmed: 19439447
Mod Pathol. 2006 Aug;19(8):1108-16
pubmed: 16680155
J Am Heart Assoc. 2015 Jun 12;4(6):e001712
pubmed: 26071033
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Anat Rec (Hoboken). 2013 Mar;296(3):427-32
pubmed: 23175429
Heliyon. 2018 Jul 18;4(7):e00695
pubmed: 30094365
Front Oncol. 2018 Sep 21;8:391
pubmed: 30298118
Cancer Lett. 2013 May 1;331(2):192-9
pubmed: 23321499
Transl Lung Cancer Res. 2018 Jun;7(3):220-233
pubmed: 30050761
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Physiol Renal Physiol. 2013 Jul 1;305(1):F100-10
pubmed: 23657850
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008
Oncogene. 2001 Mar 22;20(12):1455-64
pubmed: 11313889
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
J Virol. 2001 Dec;75(23):11791-802
pubmed: 11689660
Nat Commun. 2017 Mar 03;8:14639
pubmed: 28256511